Stay updated on Efficacy of Nintedanib + Sildenafil in IPF Clinical Trial

Sign up to get notified when there's something new on the Efficacy of Nintedanib + Sildenafil in IPF Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efficacy of Nintedanib + Sildenafil in IPF Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy and safety assessment of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:15.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as informed consent, age, health conditions, and prior treatments. Previously, this section only indicated that no information was provided.
    Difference
    30%
    Check dated 2024-05-22T21:11:39.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:28:47.000Z thumbnail image

Stay in the know with updates to Efficacy of Nintedanib + Sildenafil in IPF Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efficacy of Nintedanib + Sildenafil in IPF Clinical Trial page.